CARLSBAD, Calif., Oct. 23, 2024 /PRNewswire/ -- Tyra Biosciences, Inc. (Nasdaq: TYRA), a clinical-stage biotechnology company focused on developing next-generation precision medicines that target large opportunities in Fibroblast Growth Factor Receptor (FGFR) biology, today announced that it will host a conference call and webcast on October 25, 2024 at 8:00 am ET to share interim clinical results of TYRA-300 from the SURF301 Phase 1/2 study in metastatic urothelial cancer (mUC). These data will be presente ...

This article is published by Terry Chrisomalis, who runs the Biotech Analysis Central pharmaceutical service on Seeking Alpha Marketplace. If you like what you read here and would like to subscribe to, I'm currently offering a two-week free trial period for subscribers to take advantage of. My service offers a deep-dive analysis of many pharmaceutical companies. The Biotech Analysis Central SA marketplace is $49 per month, but for those who sign up for the yearly plan will be able to take advantage of a 33. ...

BofA Securities has upgraded Tyra Biosciences TYRA, a clinical-stage biotechnology company focused on developing next-generation precision medicines. The company's initial focus is on improving small molecule drug discovery and development in targeted oncology and genetically defined conditions. The company has a pipeline of four preclinical candidates. In July, Tyra Biosciences announced preclinical proof-of-concept results with TYRA-300 in hypochondroplasia (HCH), the most common form of dwarfism. TYRA-30 ...

-Dr. Warner brings over twenty years of proven clinical development leadership to TYRA having successfully led global development and secured approvals for medicines across oncology and skeletal disease- CARLSBAD, Calif., Sept. 10, 2024 /PRNewswire/ -- Tyra Biosciences, Inc. (Nasdaq: TYRA), a clinical-stage biotechnology company focused on developing next-generation precision medicines that target large opportunities in Fibroblast Growth Factor Receptor (FGFR) biology, announced today the appointment of Dou ...

Tyra Biosciences, Inc. (TYRA) closed the last trading session at $20.59, gaining 2.5% over the past four weeks, but there could be plenty of upside left in the stock if short-term price targets set by Wall Street analysts are any guide. The mean price target of $26.33 indicates a 27.9% upside potential. The average comprises six short-term price targets ranging from a low of $22 to a high of $33, with a standard deviation of $3.78. While the lowest estimate indicates an increase of 6.9% from the current pri ...

- SURF301 Ph1 initial results and ACH IND submission expected in 2H24 - - Reported preclinical proof-of-concept with TYRA-300 in HCH, demonstrating increases in long bone length and binding against the HCH altered protein - - IND cleared for TYRA-430, an FGFR4/3 biased inhibitor for HCC - - Announced Chief Medical Officer transition plan; search for an external candidate underway with guidance from Science & Technology (S&T) Committee of the Board, including recent additions Dr. Susan Moran and Dr. S. Micha ...

Core Insights - Tyra Biosciences, Inc. announced preclinical proof-of-concept results for TYRA-300, an investigational oral FGFR3 selective inhibitor, in hypochondroplasia (HCH) at the 6th Annual Achondroplasia & Skeletal Dysplasia Research Conference [1][2] Company Overview - Tyra Biosciences is a clinical-stage biotechnology company focused on developing next-generation precision medicines targeting FGFR biology, utilizing its in-house precision medicine platform, SNÅP, for rapid drug design [4] - The company is based in Carlsbad, California, and aims to address large opportunities in targeted oncology and genetically defined conditions [4] Product Development - TYRA-300 has shown promising preclinical results in increasing long bone length and improving growth plate function in a hypochondroplasia mouse model [6][7] - The drug targets the FGFR3 gene, which is commonly mutated in HCH, with no current approved therapeutic options available [6] - The company plans to submit an Investigational New Drug (IND) application in the second half of 2024 to initiate a Phase 2 clinical study in pediatric achondroplasia [2][7] Clinical Study Insights - In preclinical studies, TYRA-300 demonstrated significant increases in the length of various bones in FGFR3 mutated mice, including femur (3.70%), tibia (3.75%), humerus (3.22%), and ulna (5.03%) [9] - The drug also increased the size of the foramen magnum by 5.88% in the same model [9] - TYRA-300 is currently being evaluated in a multicenter, open-label Phase 1/2 clinical study for advanced solid tumors, aiming to determine the recommended Phase 2 dose and evaluate preliminary antitumor activity [7]

Core Viewpoint - Tyra Biosciences, Inc. (TYRA) has been upgraded to a Zacks Rank 2 (Buy), indicating a positive outlook on its earnings estimates and potential stock price increase [1][2][3]. Earnings Estimates and Rating Upgrade - The recent upgrade reflects an upward trend in earnings estimates, which is a significant factor influencing stock prices [1][2]. - Over the past three months, the Zacks Consensus Estimate for Tyra Biosciences has increased by 12.6% [5]. - The upgrade positions Tyra Biosciences in the top 20% of Zacks-covered stocks based on estimate revisions, suggesting potential for stock price appreciation in the near term [15]. Zacks Rating System - The Zacks Rank system classifies stocks into five groups based on earnings estimates, with Zacks Rank 1 (Strong Buy) stocks historically generating an average annual return of +25% since 1988 [4]. - The Zacks rating system maintains a balanced distribution of 'buy' and 'sell' ratings, ensuring that only the top 20% of stocks are rated favorably, which indicates superior earnings estimate revisions [10]. Earnings Outlook - For the fiscal year ending December 2024, Tyra Biosciences is expected to report earnings of -$1.71 per share, reflecting a change of -5.6% from the previous year [9].

TD Cowen's 5th Annual Oncology Innovation Summit: Insights for ASCO & EHA, May 28-29, 2024: Todd Harris, CEO of TYRA, will participate in a fireside chat on Tuesday, May 28, 2024, at 1:00 pm ET. Jefferies Global Healthcare Conference, June 5-6, 2024: TYRA management will participate in one- on-one meetings with investors during the conference. 45th Annual Goldman Sachs Global Healthcare Conference, June 10-13, 2024: Todd Harris, CEO of TYRA, will present on Wednesday, June 12, 2024, at 8:40 am ET. TYRA mana ...

Financial Performance - The company reported net losses of $18.2 million for Q1 2024, compared to $11.9 million for Q1 2023, with an accumulated deficit of $183.0 million as of March 31, 2024[76]. - Net loss for Q1 2024 was $18.2 million compared to a net loss of $11.9 million in Q1 2023, reflecting an increase in loss of 53.5%[88]. - Other income increased to $4.1 million in Q1 2024 from $2.5 million in Q1 2023, a growth of 64.0%[94]. - Total operating expenses for Q1 2024 were $22.3 million, compared to $14.3 million in Q1 2023, marking an increase of 55.8%[88]. Cash and Financing - Cash, cash equivalents, and marketable securities totaled $382.5 million as of March 31, 2024, expected to fund operations through at least 2026[80]. - Net cash used in operating activities was $22.0 million in Q1 2024, up from $9.8 million in Q1 2023, representing an increase of 124.5%[102]. - Net cash provided by financing activities was $200.3 million in Q1 2024, significantly higher than $0.4 million in Q1 2023[106]. - The company completed a private placement in February 2024, raising approximately $200 million from the sale of 9,286,023 shares of common stock and warrants[77]. - The company completed a private placement in February 2024, raising approximately $200 million before expenses[96]. - Future capital requirements will depend on various factors, including the ability to generate product revenues and the costs associated with clinical trials[110]. Research and Development - Research and development expenses are expected to increase significantly as the company advances its product candidates through clinical trials[83]. - Research and development expenses increased to $17.2 million in Q1 2024 from $10.4 million in Q1 2023, a rise of 65.2%[89]. - The lead product candidate, TYRA-300, is in a Phase 1 clinical trial (SURF301) for FGFR3+ advanced solid tumors, with initial results expected in the second half of 2024[71]. - TYRA-300 showed significant preclinical results in achondroplasia, increasing body length in mice by 17.9% and femur length by 22.6%[72]. - The company plans to submit an IND application for TYRA-300 for achondroplasia in the second half of 2024, focusing on safety and tolerability in children[73]. - The second product candidate, TYRA-200, is in a Phase 1 clinical study (SURF201) targeting FGFR2+ cholangiocarcinoma and other advanced solid tumors[74]. General and Administrative Expenses - General and administrative expenses are anticipated to rise due to increased research and development activities and costs associated with being a public company[87]. - General and administrative expenses rose to $5.1 million in Q1 2024 from $3.9 million in Q1 2023, an increase of 30.8%[93].